CA2888856A1 - Comprime dispersible - Google Patents

Comprime dispersible Download PDF

Info

Publication number
CA2888856A1
CA2888856A1 CA2888856A CA2888856A CA2888856A1 CA 2888856 A1 CA2888856 A1 CA 2888856A1 CA 2888856 A CA2888856 A CA 2888856A CA 2888856 A CA2888856 A CA 2888856A CA 2888856 A1 CA2888856 A1 CA 2888856A1
Authority
CA
Canada
Prior art keywords
pharmaceutical composition
tablet
nimorazole
water
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2888856A
Other languages
English (en)
Inventor
Nilesh TANHAJI DUMBRE
Mahesh MOHANRAO BHADGALE
Vardhaman CHANDRAKANT BAFNA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Azanta AS
Original Assignee
Azanta AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/680,216 external-priority patent/US8703188B1/en
Priority claimed from DK201270714A external-priority patent/DK177906B1/en
Application filed by Azanta AS filed Critical Azanta AS
Publication of CA2888856A1 publication Critical patent/CA2888856A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2888856A 2012-11-19 2013-11-18 Comprime dispersible Abandoned CA2888856A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US13/680,216 2012-11-19
DKPA201270714 2012-11-19
US13/680,216 US8703188B1 (en) 2012-11-19 2012-11-19 Dispersible tablet
DK201270714A DK177906B1 (en) 2012-11-19 2012-11-19 Dispersible tablet
PCT/DK2013/050384 WO2014075692A1 (fr) 2012-11-19 2013-11-18 Comprimé dispersible

Publications (1)

Publication Number Publication Date
CA2888856A1 true CA2888856A1 (fr) 2014-05-22

Family

ID=49683383

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2888856A Abandoned CA2888856A1 (fr) 2012-11-19 2013-11-18 Comprime dispersible

Country Status (12)

Country Link
EP (1) EP2919754A1 (fr)
JP (1) JP2015537013A (fr)
AU (1) AU2013347264B2 (fr)
BR (1) BR112015011408A2 (fr)
CA (1) CA2888856A1 (fr)
EA (1) EA201590732A1 (fr)
MX (1) MX2015006217A (fr)
NZ (1) NZ707033A (fr)
RU (1) RU2015117921A (fr)
TN (1) TN2015000156A1 (fr)
WO (1) WO2014075692A1 (fr)
ZA (1) ZA201502896B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3250182B1 (fr) * 2015-01-27 2023-04-26 Janssen Pharmaceutica NV Compositions dispersibles
US11324734B2 (en) 2015-04-01 2022-05-10 Akebia Therapeutics, Inc. Compositions and methods for treating anemia

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070264330A1 (en) * 2006-05-15 2007-11-15 Bo Ragnar-Tolf Pharmaceutical formulations of pimavanserin
JP2008081448A (ja) * 2006-09-28 2008-04-10 Kowa Pharmaceutical Co Ltd 酒石酸ゾルピデムの苦味マスキング速放性粒子
US20080131467A1 (en) * 2006-11-30 2008-06-05 Dennis Nelson Film-coated solid dosage form
TR201901905T4 (tr) * 2009-12-11 2019-03-21 Sumitomo Dainippon Pharma Co Ltd Kuru kaplanmış ağızda dağılan tablet.
EP2558090A4 (fr) * 2010-04-14 2013-05-08 Eupharma Pty Ltd Compositions radio-sensibilisatrices

Also Published As

Publication number Publication date
EA201590732A1 (ru) 2016-01-29
MX2015006217A (es) 2015-11-16
JP2015537013A (ja) 2015-12-24
WO2014075692A1 (fr) 2014-05-22
TN2015000156A1 (en) 2016-10-03
NZ707033A (en) 2016-11-25
ZA201502896B (en) 2016-11-30
AU2013347264A1 (en) 2015-05-07
RU2015117921A (ru) 2017-01-10
AU2013347264B2 (en) 2016-10-27
BR112015011408A2 (pt) 2017-07-11
EP2919754A1 (fr) 2015-09-23

Similar Documents

Publication Publication Date Title
JP6932746B2 (ja) エンザルタミドの製剤
TWI778983B (zh) 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
JP6325627B2 (ja) 口腔内崩壊錠及びその製造方法
JP6041919B2 (ja) ８−［｛１−（３，５−ビス−（トリフルオロメチル）フェニル）−エトキシ｝−メチル］−８−フェニル−１，７−ジアザ−スピロ［４．５］デカン−２−オンの塩を含む錠剤処方物およびそれから作製される錠剤
CN100379407C (zh) 生产咀嚼分散片的方法
TW201000472A (en) New solid pharmaceutical formulations comprising BIBW 2992
JP2010525082A (ja) 固体投与形
WO2011071139A1 (fr) Comprimé enrobé à sec à désintégration orale
KR102408085B1 (ko) 아세트아미노펜 제제의 제조 방법
KR20100099113A (ko) 만니톨 및/또는 미세결정질 셀룰로스를 포함하는 지보텐탄 조성물
JP2022105754A (ja) 緩下用錠剤
AU2013347264B2 (en) Dispersible tablet
US8741344B1 (en) Dispersible tablet
CN108420798A (zh) 一种抗凝剂的速释药物制剂及其制备方法
US20150283083A1 (en) Dispersible Tablet
CN115177595A (zh) 一种噁拉戈利钠片剂及其制备方法
KR102598782B1 (ko) 알펠리십을 포함하는 제약 조성물
DK177906B1 (en) Dispersible tablet
JP7250305B2 (ja) メマンチン又はその薬物学的に許容される塩を含む医薬組成物及びその製造方法
TW201446287A (zh) 適合對兒童投予之快速崩解錠及其簡便之製造方法
JP2006022060A (ja) 制酸・緩下用水分散液およびそのための錠剤
JP2008519834A (ja) 低水溶性薬物とともに使用することによく適した圧縮固体状投与形態の製造方法およびそれにより製造された圧縮固体状投与形態
KR101625344B1 (ko) 세레콕시브 및 둘록세틴을 함유하는 약제학적 조성물
TW202333702A (zh) 具有優異溶出性之醫藥組成物
CN115803020A (zh) 含有苯磺酸米洛巴林的口腔崩解片剂

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150421

FZDE Dead

Effective date: 20190326